Dogwood therapeutics, inc. receives nasdaq confirmation of compliance

Atlanta, april 11, 2025 (globe newswire) -- dogwood therapeutics, inc. (nasdaq: dwtx) (the “company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from nasdaq that it has regained compliance with nasdaq listing rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million.
NDAQ Ratings Summary
NDAQ Quant Ranking